AU5080393A - Bystander suppression of retroviral-associated neurological disease - Google Patents

Bystander suppression of retroviral-associated neurological disease

Info

Publication number
AU5080393A
AU5080393A AU50803/93A AU5080393A AU5080393A AU 5080393 A AU5080393 A AU 5080393A AU 50803/93 A AU50803/93 A AU 50803/93A AU 5080393 A AU5080393 A AU 5080393A AU 5080393 A AU5080393 A AU 5080393A
Authority
AU
Australia
Prior art keywords
retroviral
neurological disease
bystander suppression
associated neurological
bystander
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50803/93A
Inventor
David A. Hafler
Howard L. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autoimmune Inc
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of AU5080393A publication Critical patent/AU5080393A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Rehabilitation Therapy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU50803/93A 1992-08-17 1993-08-17 Bystander suppression of retroviral-associated neurological disease Abandoned AU5080393A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93121792A 1992-08-17 1992-08-17
PCT/US1993/007786 WO1994004121A1 (en) 1992-08-17 1993-08-17 Bystander suppression of retroviral-associated neurological disease
US931217 2001-08-16

Publications (1)

Publication Number Publication Date
AU5080393A true AU5080393A (en) 1994-03-15

Family

ID=25460408

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50803/93A Abandoned AU5080393A (en) 1992-08-17 1993-08-17 Bystander suppression of retroviral-associated neurological disease

Country Status (4)

Country Link
JP (1) JPH08500823A (en)
AU (1) AU5080393A (en)
IL (1) IL106720A (en)
WO (1) WO1994004121A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2470595A (en) * 1994-05-10 1995-11-29 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
HUT77047A (en) * 1994-10-25 1998-03-02 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
CA2276450C (en) * 1997-01-02 2013-02-19 Thomas Jefferson University A method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent
PT1005374E (en) * 1997-01-22 2007-07-18 Mgi Pharma Biolog Inc Microparticles for delivery of nucleic acid
EP1286686B1 (en) 2000-05-24 2007-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES E-selectin for treating or preventing stroke

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659235A1 (en) * 1990-03-09 1991-09-13 Asahi Chemical Ind APPLICATION OF THE TUMOR FACTOR OF NECROSE TO THE TREATMENT OF DEMYELINIZATION DISORDERS, UVEITIS OR HOST DISORDERS THAT HAVE RECEIVED A GRAFT.

Also Published As

Publication number Publication date
WO1994004121A1 (en) 1994-03-03
JPH08500823A (en) 1996-01-30
IL106720A0 (en) 1993-12-08
IL106720A (en) 1998-10-30

Similar Documents

Publication Publication Date Title
AU7250294A (en) Treatment of multidrug resistant diseases
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
IL105966A (en) Preparation of clavulanic acid
IL111122A0 (en) Methods of stimulating phagocytosis
AU1173195A (en) Treatment of immunoregulatory disorders
AU7334194A (en) Characteristic of body part determined
AU8153794A (en) Methods of inhibiting autoimmune diseases
AU4792293A (en) Impact modification of polyamides
AU3263493A (en) Tonometer
AU3810093A (en) Methods of achieving antitumor activity using 16-membered-macrolide-type compounds
AU3375093A (en) Treatment of mineral tailings
AU5080393A (en) Bystander suppression of retroviral-associated neurological disease
AU5737494A (en) Human thrombospondin-4
IL104755A0 (en) Treatment of glaucoma
AU3724593A (en) Polyfluoroalkylation of aromatic compounds
AU5252793A (en) Therapeutic for gram-positive diseases of aquatic species
AU5430894A (en) Diagnosis of eye disorders
GB2265623B (en) Preparation of n-vinyl-o-alkyl carbamate
AU3632093A (en) Combinations of compounds having antiviral activity
GB8715973D0 (en) Protection of vehicles against obstacles
HU9303222D0 (en) Suppression of autoignition
AU3518693A (en) Therapeutic earring
AU5165993A (en) Pp14-based therapy
EP0553954A3 (en) Preparation of tetramethyldiamino-polyoxyethylenes
AU7695891A (en) Treatment of autoimmune diseases